Selective activation of p53-mediated tumour suppression in high-grade tumours

Article metrics

Abstract

Non-small cell lung carcinoma (NSCLC) is the leading cause of cancer-related death worldwide, with an overall 5-year survival rate of only 10–15%1. Deregulation of the Ras pathway is a frequent hallmark of NSCLC, often through mutations that directly activate Kras2. p53 is also frequently inactivated in NSCLC and, because oncogenic Ras can be a potent trigger of p53 (ref. 3), it seems likely that oncogenic Ras signalling has a major and persistent role in driving the selection against p53. Hence, pharmacological restoration of p53 is an appealing therapeutic strategy for treating this disease4. Here we model the probable therapeutic impact of p53 restoration in a spontaneously evolving mouse model of NSCLC initiated by sporadic oncogenic activation of endogenous Kras5. Surprisingly, p53 restoration failed to induce significant regression of established tumours, although it did result in a significant decrease in the relative proportion of high-grade tumours. This is due to selective activation of p53 only in the more aggressive tumour cells within each tumour. Such selective activation of p53 correlates with marked upregulation in Ras signal intensity and induction of the oncogenic signalling sensor p19 ARF(ref. 6). Our data indicate that p53-mediated tumour suppression is triggered only when oncogenic Ras signal flux exceeds a critical threshold. Importantly, the failure of low-level oncogenic Kras to engage p53 reveals inherent limits in the capacity of p53 to restrain early tumour evolution and in the efficacy of therapeutic p53 restoration to eradicate cancers.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Heterogeneous therapeutic impact of p53 restoration in Kras G12D -driven lung tumours.
Figure 2: Heterogeneous p53 activation and p19 ARF upregulation in KR;p53 KI/KI tumours.
Figure 3: p53 restoration targets high-grade, but not low-grade, lung tumour cells.
Figure 4: High-grade lung tumours exhibit increased Kras signalling.

References

  1. 1

    Jemal, A. et al. Cancer statistics, 2006. CA Cancer J. Clin. 56, 106–130 (2006)

  2. 2

    Meuwissen, R. & Berns, A. Mouse models for human lung cancer. Genes Dev. 19, 643–664 (2005)

  3. 3

    Serrano, M., Lin, A., McCurrach, M., Beach, D. & Lowe, S. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a . Cell 88, 593–602 (1997)

  4. 4

    Wang, W. & El-Deiry, W. S. Restoration of p53 to limit tumor growth. Curr. Opin. Oncol. 20, 90–96 (2008)

  5. 5

    Jackson, E. L. et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras . Genes Dev. 15, 3243–3248 (2001)

  6. 6

    Kamijo, T. et al. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19 ARF . Cell 91, 649–659 (1997)

  7. 7

    Martins, C. P., Brown-Swigart, L. & Evan, G. I. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 127, 1323–1334 (2006)

  8. 8

    Ventura, A. et al. Restoration of p53 function leads to tumour regression in vivo . Nature 445, 661–665 (2007)

  9. 9

    Xue, W. et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445, 656–660 (2007)

  10. 10

    Christophorou, M. A., Ringshausen, I., Finch, A. J., Swigart, L. B. & Evan, G. I. The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. Nature 443, 214–217 (2006)

  11. 11

    Murphy, D. J. et al. Distinct thresholds govern Myc’s biological output in vivo . Cancer Cell 14, 447–457 (2008)

  12. 12

    Sarkisian, C. J. et al. Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nature Cell Biol. 9, 493–505 (2007)

  13. 13

    Sweet-Cordero, A. et al. An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nature Genet. 37, 48–55 (2005)

  14. 14

    Christophorou, M. A. et al. Temporal dissection of p53 function in vitro and in vivo . Nature Genet. 37, 718–726 (2005)

  15. 15

    Jackson, E. L. et al. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res. 65, 10280–10288 (2005)

  16. 16

    Dulic´, V. et al. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76, 1013–1023 (1994)

  17. 17

    El Deiry, W. S. et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 54, 1169–1174 (1994)

  18. 18

    Feldser, D. et al. Stage-specific sensitivity to p53 restoration in lung cancer. Nature doi:10.1038/nature09535. (in the press)

  19. 19

    Palmero, I., Pantoja, C. & Serrano, M. p19ARF links the tumour suppressor p53 to Ras. Nature 395, 125–126 (1998)

  20. 20

    Nikitin, A. Y. et al. Classification of proliferative pulmonary lesions of the mouse: recommendations of the mouse models of human cancers consortium. Cancer Res. 64, 2307–2316 (2004)

  21. 21

    Guerra, C. et al. Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell 4, 111–120 (2003)

  22. 22

    Tuveson, D. A. et al. Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 5, 375–387 (2004)

  23. 23

    Vicent, S. et al. ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours. Br. J. Cancer 90, 1047–1052 (2004)

  24. 24

    Shaw, A. T. et al. Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis. Genes Dev. 21, 694–707 (2007)

  25. 25

    Wagner, P. L. et al. In situ evidence of KRAS amplification and association with increased p21 levels in non-small cell lung carcinoma. Am. J. Clin. Pathol. 132, 500–505 (2009)

  26. 26

    Zhang, Z. et al. Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells. Carcinogenesis 31, 577–586 (2010)

  27. 27

    Zhang, Z. et al. Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nature Genet. 29, 25–33 (2001)

  28. 28

    Junttila, M. R. & Evan, G. I. p53 – a Jack of all trades but master of none. Nature Rev. Cancer 9, 821–829 (2009)

  29. 29

    Bertwistle, D., Zindy, F., Sherr, C. J. & Roussel, M. F. Monoclonal antibodies to the mouse p19Arf tumor suppressor protein. Hybrid. Hybridomics 23, 293–300 (2004)

  30. 30

    Lawlor, E. R. et al. Reversible kinetic analysis of Myc targets in vivo provides novel insights into Myc-mediated tumorigenesis. Cancer Res. 66, 4591–4601 (2006)

Download references

Acknowledgements

We are indebted to T. Jacks for the KR mice, C. Sherr and M. Roussel for the p19 ARF antibody, M. Dail and A.-T. Maia for advice on Kras copy number analysis and V. Weinberg for guidance on statistical analysis. We also thank D. Tuveson and all the members of the Evan laboratory for their comments. This work was supported by grants NCI CA98018, NCI CA100193, AICR 09-0649, the Ellison Medical Foundation and from the Samuel R. Waxman Cancer Research Foundation (all to G.I.E.). M.R.J. is the Enrique Cepero, PhD Fellow of the Damon Runyon Cancer Research Foundation.

Author information

C.P.M. and G.I.E. designed this study with help from M.R.J. C.P.M. and M.R.J. performed all experiments with assistance from D.G. and F.M. C.P.M., M.R.J. and G.I.E. analysed and interpreted the data. A.N.K. graded all tumours. L.B.S., F.R. and R.M.K. helped maintain the mouse colony. D.M.P. and Y.S. performed the micro-computed tomography analysis. C.P.M. and G.I.E. wrote the paper with help from M.R.J. and all authors contributed to editing.

Correspondence to Gerard I. Evan.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Figures

The file contains Supplementary Figures 1-9 with legends. (PDF 2689 kb)

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Junttila, M., Karnezis, A., Garcia, D. et al. Selective activation of p53-mediated tumour suppression in high-grade tumours. Nature 468, 567–571 (2010) doi:10.1038/nature09526

Download citation

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.